Having employers and accountable care organizations agree on expectations is necessary for better alignment of care offered, explained Brian Marcotte, president and CEO of the National Business Group on Health.
Having employers and accountable care organizations agreeing on expectations is necessary for better alignment of care offered, explained Brian Marcotte, president and CEO of the National Business Group on Health.
Transcripts (slightly modified)
Does there need to be better alignment between what employers are looking for from an accountable care organization (ACO) and what ACOs are offering?
I think it’s really more about agreeing on what expectations are and making sure expectations are aligned. So, an early-stage ACO is going to focus primarily on the 5% of the population that drives 50% of the cost—the better care coordination, better management within the provider community, and the specialty community. What does that mean for the rest of the population? It doesn’t mean much.
So, from an employer perspective, I just want to know where this ACO is from a developmental standpoint, so I know what to communicate to my members. If it’s an early-stage ACO, an employer who has chronic conditions and an employee who is fairly healthy, is not going to seem much different. A later-stage ACO, who’s doing more outreach to chronic patients and moderate-risk patients—well there is something different there. So, it’s really aligning expectations.
There’s nothing wrong with an early-stage ACO, it’s just understanding that it’s early stage, and you will see things different from that then you will from an ACO that’s more mature.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More